Diabetes and Cardiovascular disease following kidney transplantation

Current Diabetes Reviews

Volumn 7, Issue 4, 2011, Pages 221-234

  Boerner, Brian P ^b   Shivaswamy, Vijay ^a,b   Desouza, Cyrus V ^a,b   Larsen, Jennifer L ^a,b  

^a VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; Diabetes; Dyslipidemia; Hypertension; Kidney transplant; Obesity

Indexed keywords

ACARBOSE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; EZETIMIBE; FLUINDOSTATIN; GLIPIZIDE; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA; URIC ACID; VITAMIN D;

ADRENAL FUNCTION; ALBUMINURIA; ANEMIA; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; DIABETES MELLITUS; DYSLIPIDEMIA; EDEMA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; META ANALYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVENTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; TYPE 2 DIABETES;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MODELS, BIOLOGICAL; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 79960977536     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911796397857     Document Type: Review

References (174)

1. United States Renal Data System. USRDS 2010 Annual Data Report: Atlas of of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2010.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney diesase and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
3. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010; 341: c4986. doi: 10.1136/bmj.c4986; [E-pub ahead of print].
4. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-30.
5. Brunkhorst R, Lufft V, Dannenberg B, Kliem V, Tusch G, Pichlmayr R. Improved survival in patients with type 1 diabetes mellitus after renal transplantation compared with hemodialysis: a case- control study. Transplantation 2003; 76: 115-9.
6. Lindholm A, Albrechtsen D, Frödin L, Tufveson G P N, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in scandinavia. Transplantation 1995; 60: 451-7.
7. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-13.
8. Arend SM, Mallat MJK, Westendopr RJW, van der Woude FJ, van Es LA. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol Dial Transplant 1997; 12: 1672-9.
9. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes 2004; 2: 2.
10. Nakjima K, Ochiai T, Suzuki T, et al. Beneficial effects of renal transplantation on cardiovascular disorders in dialysis patients. Surg Today 1998; 28: 811-5.
11. Orchard TJ, Secrest AM, Miller RG, Costacou T. In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the pittsburgh epidemiology of diabetes complications study. Diabetologia 2010; 53: 2312-9.
12. Gowdak LHW, de Paula FJ, César LAM, et al. Diabetes and coronary artery disease impose similar cardiovascular morbidity and mortality on renal transplant candidates. Nephrol Dial Transplant 2007; 22: 1456-61.
13. Aalten J, Hoogeveen EK, Roodnat JI, et al. Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death. Transplant Int 2008; 21: 985-91.
14. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-43.
15. Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the framingham risk score revisited. Clin J Am Soc Nephrol 2008; 3: 822-8.
16. Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellström B. Renal transplant dysfunction - importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282-9.
17. Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study. Am J Transplant 2010; 10: 338-53.
18. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: SS3-24.
19. Ali IH, Adberrahim E, Ben Abdelghani K, et al. Incidence and risk factors for post-renal transplant diabetes mellitus. Transplant Proc 2011; 43(2): 568-71.
20. Madziarska K, Weyde W, Krajewska M, et al. The increased risk of post-transplant diabetes mellitus in peritoneal dialysis-treated kidney allograft recipients. Nephrol Dial Transplant 2011; 26(4): 1396-401.
21. Mazali FC, Lalli CA, Alves-Filho G, Mazzali M. Posttransplant diabetes mellitus: incidence and risk factors. Transplant Proc 2008; 40(3): 764-6.
22. Ramesh Prasad GV, Huang M, Bandukwala F, et al. Pretransplantation glucose testing for predicting new-onset diabetes mellitus after renal transplantation. Clin Nephrol 2009; 71(2): 140-6.
23. Sulanc E, Lane JT, Puumala SE, Groggel GC, Wrenshall LE, Stevens RB. New-onset diabetes after kidney transplantation: an application of 2003 international guidelines. Transplantation 2005; 80: 945-52.
24. Larsen JL, Bennett RG, Burkman T, et al. Tacrolimus and sirolimus cause insulin resistance in normal sprague dawley rats. Transplantation 2006; 82(4): 466-70.
25. Ozbay LA, Smidt K, Mortensen DM, Carstens J, Jorgensen KA, Rungby J. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol; 162(1): 136-46.
26. Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83(1): 36-40.
27. Ali IH, Adberrahim E, Ben Abdelghani K, et al. Incidence and risk factors for post-renal transplant diabetes mellitus. Transplant Proc 2011; 43(2): 568-71.
28. Stevens RB, Lane JT, Boerner BP, et al. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. Clin Transplant 2011. doi: 10.1111/j.1399-0012.2011.01425.x; [Epub ahead of print]
29. Van Laecke S, Van Biesen W, Verbeke F, De Bacquer D, Peeters P, Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant; 9(9): 2140-9.
30. Demirci MS, Toz H, Ertilav M, et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24: E170-E7.
31. Hjelmesæth J, Hartmann A, Leivestad T, et al. The impact of early- diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-95.
32. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496-506.
33. Aschner P. Metabolic syndrome as a risk factor for diabetes. Expert Rev Cardiovasc Ther 2010; 8: 407-12.
34. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. J Am Coll Cardiol 2010; 56: 1113-32.
35. Soveri I, Abedini S, Holdaas H, Jardine A, Ericksson N, Fellström B. Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment. Clin Transplant 2009; 23: 914-20.
36. Alvarez A, Fernandez J, Porrini E, et al. Carotid atheromatosis in nondiabetic renal transplant recipients: the role of prediabetic glucose homeostasis alterations. Transplantation 2007; 84(7): 870-5.
37. Genis BB, Granada ML, Alonso N, et al. Ghrelin, glucose homeostasis, and carotid intima media thickness in kidney transplantation. Transplantation 2007; 84(10): 1248-54.
38. Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2009; 77(4): 299-311.
39. Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test. Transplantation 2011; 91(7): 757-64.
40. Haidinger M, Werzowa J, Voigt HC, et al. A randomized, placebocontrolled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010; 11: 91.
41. America Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011; 34(Suppl 1): S11-61.
42. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Arch Intern Med 2010; 170: 1622-31.
43. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137(1): 25-33.
44. Del Prato S, Aragona M, Coppelli A. Sulfonylureas and hypoglycaemia. Diabetes Nutr Metab 2002; 15(6): 444-50; discussion 50-1.
45. Baldwin D, Jr., Duffin KE. Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 2004; 77(7): 1009-14.
46. Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6(4): 842-6.
47. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011; 342:d1309. doi: 10.1136/bmj.d1309; [E-pub ahead of print].
48. Luther P, Baldwin D, Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 2004; 4(12): 2135-8.
49. Jaakkola T, Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 2006; 99(1): 44-51.
50. th Scientific Sessions 2009. [Abstract number: 2509-PO].
51. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-86.
52. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet; 352(9131): 854-65.
53. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837-53.
54. Epidemiology of Diabetes Interventions and Complications Research Group.Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003; 290(16): 2159-67.
55. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359(15): 1577-89.
56. Young BY, Gill J, Huang E, et al. Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: an analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol 2009; 4(4): 845-52.
57. Morath C, Zeier M, Dohler B, Schmidt J, Nawroth PP, Opelz G. Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol 2008; 19(8): 1557-63.
58. Morath C, Zeier M, Dohler B, et al. Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft. Clin J Am Soc Nephrol 2010; 5(3): 549-52.
59. Larsen JL, Colling CW, Ratanasuwan T, et al. Pancreas transplanttation improves vascular disease in patients with type 1 diabetes. Diabetes Care 2004; 27(7): 1706-11.
60. Sureshkumar KK, Patel BM, Markatos A, Nghiem DD, Marcus RJ. Quality of life after organ transplantation in type 1 diabetics with end-stage renal disease. Clin Transplant 2006; 20(1): 19-25.
61. Sureshkumar KK, Mubin T, Mikhael N, Kashif MA, Nghiem DD, Marcus RJ. Assessment of quality of life after simultaneous pancreas-kidney transplantation. Am J Kidney Dis 2002; 39(6): 1300-6.
62. Warnock GL, Thompson DM, Meloche RM, et al. A multi-year analysis of islet transplantation compared with intensive medical therapy on progression of complications in type 1 diabetes. Transplantation 2008; 86(12): 1762-6.
63. Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 2005; 28(6): 1303-10.
64. Fiorina P, Gremizzi C, Maffi P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005; 28(6): 1358-65.
65. Midtvedt K, Hartmann A. Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol Dial Transplant 2002; 17: 1166-9.
66. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071-81.
67. Robert N, Wong GWK, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database of Syst Rev 2010; CD007893.
68. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab 1986; 62: 275-9.
69. Fernandez-Fresnedo G, Palomar R, Escallada R, et al. Hypertension and long-term renal allograft survival: effect of early glomerular filtration rate. Nephrol Dial Transplant 2001; 16(Suppl 1): 105-9.
70. Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol 2004; 15: 134-41.
71. Ducloux D, Motte G, Kribs M, et al. Hypertension in renal transplantation: donor and recipient risk factors. Clin Nephrol 2002; 57: 409-13.
72. Guidi E, Menghetti D, Milani S, et al. Hypertension may be transplanted with the kidney in humans: a long-term historical perspective follow-up of recipients grafted with kidney coming from donors with or without hypertension. J Am Soc Nephrol 1996; 7: 1131-8.
73. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358(9290): 1305-15.
74. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
75. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5(11): 2725-31.
76. Hillebrand U, Suwelack BM, Loley K, et al. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients. Transpl Int 2009; 22(11): 1073-80.
77. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17(Suppl 4): 1-67.
78. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560-72.
79. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(5 Suppl 1): S1-290.
80. Larsen JL, Groggel GC, Witte JM, et al. Association of vascular risk factors with carotid intima media thickness after kidney transplant. Transplantation 2010; 90(9): 980-5.
81. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329(20): 1456-62.
82. Splawinski JA. Mediation of hyperthermia by prostaglandin E2: a new hypothesis. Naunyn Schmiedebergs Arch Pharmacol 1977; 297(Suppl 1): S95-7.
83. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7(10): 2350-60.
84. Ruggenenti P, Perico N, Mosconi L, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43(3): 706-11.
85. Midtvedt K, Hartmann A, Foss A, et al. Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001; 72(11): 1787-92.
86. Przybylowski P, Malyszko J, Malyszko JS, Kobus G, Sadowski J, Mysliwiec M. Blood pressure control in orthotopic heart transplant and kidney allograft recipients is far from satisfactory. Transplant Proc 2010; 42(10): 4263-6.
87. Kimura H, Suzuki Y, Gejyo F, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 1998; 31(4): 666-73.
88. Holdaas H, Fellström B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929-36.
89. Barn K, Laftavi M, Pierce D, Ying C, Boden WE, Pankewycz O. Low levels of high-density lipoprotein cholesterol: an independent risk factor for late adverse cardiovascular events in renal transplant recipients. Transplant Int 2009; 23: 574-9.
90. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361(9374): 2024-31.
91. Abedini S, Holme I, Fellstrom B, et al. Cerebrovascular events in renal transplant recipients. Transplantation 2009; 87(1): 112-7.
92. Younas N, Wu CM, Shapiro R, et al. HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival. BMC Nephrol 2010; 11: 5.
93. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001; 1(4): 382-6.
94. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62(11): 1559-64.
95. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001; 158(2): 417-23.
96. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997; 62(3): 311-21.
97. Aliabadi AZ, Mahr S, Dunkler D, et al. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 2008; 86(12): 1771-6.
98. Kovarik JM, Hartmann S, Hubert M, et al. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol 2002; 42(2): 222-8.
99. Savvidaki E, Koukoulaki M, Benou A, et al. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Clin Nephrol 2011; 75(2): 107-12.
100. Fernandez-Bussy S, Akindipe O, Baz M, Gosain P, Rosenberg A, Zumberg M. Sirolimus-induced severe hypertriglyceridemia in a lung transplant recipient. Transplantation 2010; 89(4): 481-2.
101. Hoogeveen EK, Aalten J, Rothman KJ, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow up. Transplantation 2011; 91(8): 869-74.
102. Kovesdy CP, Czira ME, Rudas A, et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010; 10: 2644-51.
103. Haslam D. Obesity and diabetes: the links and common approaches. Prim Care Diabetes 2010; 4(2): 105-12.
104. Kalantar-zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81: 543-54.
105. Postorino M, Marino C, Tripepi G, Zoccali C. Abdominal obesity and all-cause and cardiovascular mortality in end-stage renal disease. J Am Coll Cardiol 2009; 53: 1265-72.
106. Lentine KL, Rocca Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation 2008; 86: 303-12.
107. Gombos P, Langer RM, Korbely R, et al. Smoking following renal transplantation in Hungary and its possible deleterious effects on renal graft function. Transplant Proc 2010; 42: 2357-9.
108. Zitt N, Kollerits B, Neyer U, et al. Cigarette smoking and chronic allograft nephropathy. Nephrol Dial Transplant 2007; 22: 3034-9
109. Xu CB, Sung Y, Edvinsson L. Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharmacol Ther 2010; 127: 148-55.
110. Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001; 71: 1752-7.
111. Knoll GA. Proteinuria in kidney transplant recipients: prevalence, prognosis, and evidence-based management. Am J Kidney Dis 2009; 54: 1131-44.
112. Prasad GVR, Lipszyc D, Huang M, Nash MM, Rapi L. A prospective observational study of changes in renal function and cardiovascular risk following living kidney donation. Transplantation 2008; 86: 1315-8.
113. Moore J, Shabir S, Chand S, et al. Assessing and comparing rival definitions of delayed renal allograft function for predicting subsequent graft failure. Transplantation 2010; 90: 1113-6.
114. Khalkhali HR, Ghafari A, Hajizadeh E, Kazemnejad A. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction. Exp Clin Transplant 2010; 8: 277-82.
115. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia 1989; 32(4): 219-26.
116. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286(4): 421-6.
117. Yu Z, Schneck M, Jacobs DR, Jr., et al. Association of carotid intima-media thickness with progression of urine albumincreatinine ratios in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2011; 57(1): 62-70.
118. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14(2): 223-8.
119. Kramer H, Reboussin D, Bertoni AG, et al. Obesity and albuminria among adults with type 2 diabetes: the look AHEAD (Action for Health in Diabetes) Study. Diabetes Care 2009; 32(5): 851-3.
120. Meigs JB, D'Agostino RB, Sr., Nathan DM, Rifai N, Wilson PW. Longitudinal association of glycemia and microalbuminuria: the Framingham Offspring Study. Diabetes Care 2002; 25(6): 977-83.
121. Upadhyay A, Larson MG, Guo CY, et al. Inflammation, kidney function and albuminuria in the framingham offspring cohort. Nephrol Dial Transplant 2011; 26(3): 920-6.
122. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145-53.
123. Halimi JM, Matthias B, Al-Najjar A, et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007; 7: 2775-81.
124. Prasad GV, Bandukwala F, Huang M, Zaltzman JS. Microalbuminuria post-renal transplantation: relation to cardiovascular risk factors and c-reactive protein. Clin Transplant 2009; 23: 313-20.
125. Nauta FL, Bakker SJ, van Oeveren W, et al. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 57(5): 733-43.
126. Leeder SR, Mitchell P, Liew G, Rochtchina E, Smith W, Wang JJ Low hemoglobin, chronic kidney disease, and risk for coronary heart disease-related death: the Blue Mountains Eye Study. J Am Soc Nephrol 2006; 17: 279-84.
127. Vlagopoulos P, Tighiouart H, Weiner D, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16: 3403-10.
128. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoein alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-56.
129. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355(20): 2085-98.
130. Arias M, Escallada R, de Fransisco AL, et al. Return to dialysis after renal transplantation. Which would be the best way? Kidney Int 2002; Suppl 80: S85-S88.
131. Chhabra D, Grafals M, Skaro A, Parker M, Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008; 3: 1168-74.
132. Winkelmayer WC, Lorenz M, Kramar R, et al. Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients. Am J Transplant 2004; 4: 2075-81.
133. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Elevated homocysteine is a predictor of all-cause mortality in a prospective cohort of renal transplant recipients. Nephron Clin Pract 2010; 114: c5-c11.
134. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66: 441-7.
135. Massy ZA, Chadefaux-Vekemans B, Chevalier A, et al. Hyperhomocysteinemia: a significant risk factor for cardiovascular disease in renal transplant recipients. Nephrol Dial Transplant 1994; 9: 1103-8.
136. Marucci R, Zanazzi M, Bertoni E, et al. Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients. Transplantation 2003; 75: 1551-5.
137. Austen SK, Fassett RG, Geraghty DP, Coombes JS. Folate supplementation fails to affect vascular function and carotid intima media thickness in cyclosporin A-treated renal transplant recipients. Clin Nephrol 2006; 66: 373-9.
138. Kalantar E, Khalili N, Hossieni MS, Rostami Z, Einollahi B. Hyperuricemia after renal transplantation. Transplant Proc 2011; 43: 584-5.
139. Kanbay M, Akcay A, Huddam B, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005; 37: 3119-20.
140. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13(12): 2888-97.
141. Haririan A, Nogueria J, Zandi-Nejad K, et al. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation 2010; 89: 573-9.
142. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38(5): 1101-6.
143. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GVR. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 2009; 15: 867-71.
144. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.
145. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147-53.
146. La Manna G, Cappuccilli ML, Cianciolo G, et al. Cardiovascular disease in kidney transplant recipients: the prognostic value of inflammatory cytokine genotypes. Transplantation 2010; 89(8): 1001-8.
147. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4(7): 1246-54.
148. Didion SP, Kinzenbaw DA, Schrader LI, Chu Y, Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension 2009; 54(3): 619-24.
149. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19(12): 2847-53.
150. Von Der Thusen JH, Kuiper J, Fekkes Ml, De Vas, P, Van Berkeel TJ, Biessen Ea. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 2001; 15(14): 2730-2.
151. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 2007; 292(4): H1655-63.
152. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257(1): 79-83.
153. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009; 302(2): 179-88.
154. Kaisar MO, Armstrong K, Hawley C, et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrol 2009; 10: 29.
155. Koch Nogueira PC, David L, Cochat P. Evolution of secondary hyperparathyroidism after renal transplantation. Pediatr Nephrol 2000; 14(4): 342-6.
156. Marcen R, Ponte B, Rodriguez-Mendiola N, et al. Vitamin D deficiency in kidney transplant recipients: risk factors and effects of vtamin D3 supplements. Transplant Proc 2009; 41(6): 2388-90.
157. Stavroulopoulos A, Cassidy MJ, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant 2007; 7(11): 2546-52.
158. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4(3): 685-90.
159. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical impliations. Am J Transplant 2005; 5(8): 1934-41.
160. Ozdemir FN, Afsar B, Akgul A, Usluogullari C, Akcay A, Haberal M. Persistent hypercalcemia is a significant risk factor for graft dysfunction in renal transplantation recipients. Transplant Proc 2006; 38(2): 480-2.
161. Nilsson IL, Aberg J, Rastad J, Lind L. Endothelial vasodilatory dysfunction in primary hyperparathyroidism is reversed after parathyroidectomy. Surgery 1999; 126(6): 1049-55.
162. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56(2): 383-92.
163. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009; 207(2): 585-90.
164. Richart T, Thijs L, Nawrot T, et al. The metabolic syndrome and carotid intima-media thickness in relation to the parathyroid hormone to 25-OH-D(3) ratio in a general population. Am J Hypertens 2011; 24(1): 102-9.
165. Anderson JL, May HT, Horne BD, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106(7): 963-8.
166. Swales HH, Wang TJ. Vitamin D and cardiovascular disease risk: emerging evidence. Curr Opin Cardiol 2010; 25(5): 513-7.
167. London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18(2): 613-20.
168. Stack AG, Bloembergen WE. Prevalence and clinical correlates of coronary artery disease among new dialysis patietns in the United States: a cross-sectional study. J Am Soc Nephrol 2001; 12: 1516-23.
169. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). J Am Coll Cardiol 2007; 50: e159-241.
170. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of rena-transplant candidates: clinical practice guidelines. Am J Transplant 2001; 1(Suppl 2): 5-95.
171. Pilmore H. Cardiac assessment for renal transplantation. Am J Transplant 2006; 6: 659-65.
172. Welsh RC, Cockfield SM, Campbell P, Hervas-Malo M, Gyenes G, Dzavik V. Cardiovascular assessment of diabetic end-stage renal disease patients before renal transplantation. Transplantation 2011; 91: 213-8.
173. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1-S157.
174. Sibal L, Agarwal SC, Home PD. Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes Metab Syndr Obes 2011; 4: 23-34.